SCHEMBL2699657

SCHEMBL2699657

O=C(O)Nc1ccc(N2CCC[C@@]3(CCN(C4CCOCC4)C3=O)C2)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
PDE7A Q13946 2/20 0.41
HTT P42858 2/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
NPY2R P49146 3/20 0.37
LMNA P02545 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
CYP2C9 P11712 1/20 0.35
PKM P14618 1/20 0.35
CYP2C19 P33261 1/20 0.35
DGAT1 O75907 1/20 0.35
MTOR P42345 2/20 0.35
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3706571 1.00 MAPT (0.41) MAPTKMT2AMEN1PDE7AHTT
SCHEMBL2697803 0.91 MAPT (0.40) MAPTKMT2AMEN1PDE7AHTT
SCHEMBL3699097 0.91 MAPT (0.40) MAPTKMT2AMEN1PDE7AHTT
SCHEMBL2700019 0.91 MAPT (0.40) MAPTKMT2AMEN1PDE7AHTT
SCHEMBL2700025 0.91 MAPT (0.40) MAPTKMT2AMEN1PDE7AHTT
SCHEMBL2697800 0.91 MAPT (0.40) MAPTKMT2AMEN1PDE7AHTT
SCHEMBL3699091 0.91 MAPT (0.40) MAPTKMT2AMEN1PDE7AHTT
SCHEMBL17082028 0.90 PDE7A (0.40) MAPTKMT2AMEN1PDE7AHTT
SCHEMBL4570077 0.90 PDE7A (0.40) MAPTKMT2AMEN1PDE7AHTT
SCHEMBL4570081 0.89 MTOR (0.40) MAPTPDE7AHTTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2450351-A1 Lactam compounds and their use as pharmaceuticals Incyte Corporation (US) 2012-05-09 EP claimed
US-20060116382-A1 Lactam compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-01 US claimed
EP-1812005-B1 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2015-09-16 EP disclosed
EP-2450351-A1 Lactam compounds and their use as pharmaceuticals Incyte Corporation (US) 2012-05-09 EP disclosed
EP-1812005-A2 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-08-01 EP disclosed
US-20060116382-A1 Lactam compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-01 US disclosed
WO-2006053024-A2 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060116382-A1 Lactam compounds and their use as pharmaceuticals HSD11B1, HSD11B2, HSD17B1 MAPT 3735/4885KMT2A 3165/4885MEN1 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.